% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

lee.grayling 1 post  |  Last Activity: Feb 28, 2016 7:38 PM Member since: Jun 22, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • lee.grayling by lee.grayling Feb 28, 2016 7:38 PM Flag

    topline data: median PFS on the binimetinib arm was 2.8 months vs 1.5 months on decarbazine arm. If complete data shows no overall survival, on what basis does ARRY think that PFS will be enough for approval? Were other mek inhibitors approved on PFS alone? I vaguely recall that being said at one of the confreences Q&A.